March 14th 2023
This subtype of artificial intelligence technology may have long-range implications for clinical trials.
Glaucoma 360: Home tonometry - worth the pressure?
February 4th 2023Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.
Read More
Glaucoma 360: An update on IOLs - when and how to use them
February 4th 2023Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.
Read More
Glaucoma 360: A bird's-eye view of innovation
February 3rd 2023Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.
Read More
EyeCon 2022: Management options for the treatment of pediatric myopia
December 17th 2022Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.
Read More
EyeCon 2022: Ophthalmology Times co-chairs discuss highlights of Day 1
December 17th 2022Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.
Read More
EyeCon 2022: Important updates in retinopathy of prematurity for clinicians
December 17th 2022Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.
Read More
BRIM Biotechnology receives FDA orphan drug designation for treatment of neurotrophic keratitis
December 8th 2022Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
Read More
Ocuphire Pharma submits New Drug Application to FDA for Nyxol eye drops for reversal of mydriasis
December 6th 2022According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.
Read More
Boarding Orbis Flying Eye Hospital: Not your typical flight experience
November 16th 2022When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.
Read More